Neoadjuvant therapy
Title: MammaPrint® and BluePrint® Predict Pathological Response to Neoadjuvant Read More
Title: Neoadjuvant Chemotherapy for T3 tumors in the Era Read More
Title: Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Read More
Cureus, part of Springer Nature Author: Jiang et al.
Read More21st Bossche Mamma Congress 2024, P07 Presenter: O'Shaughnessy et al.
Read MoreElucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Read MoreSSO 2024 Author: Solis-Pomales et al.
Read MoreThe Breast 75 (2024) 103726 Presenter: van Olmen et al.
Read MoreJournal of Clinical Oncology, April 9, 2024 Presenter: Rios-Hoyo et al.
Read MoreEBCC 2024, Oral Presentation Presenter: Dr. Caroline Drukker
Read More
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
CHIEF COMPLIANCE OFFICER
Stephanie has worked in compliance since 2005 and has extensive experience developing and managing programs to support compliance with global, federal, and state laws and regulations in the healthcare and biotech industries. Prior to joining Agendia, Stephanie spent a significant portion of her career serving as a compliance officer in laboratories, such as HealthTrackRx, NeoGenomics, and Myriad Genetics, and held compliance leadership roles in medical device, pharma, and large health systems.
Stephanie graduated Summa Cum Laude with a B.S. in Healthcare Administration from Northern Illinois University and is Certified in Healthcare Compliance (CHC), Data Privacy (CHP), Research Compliance (CHRC), and is a Certified Internal Auditor (CIA).
